NCT01077570View on ClinicalTrials.gov

An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese Patients

CompletedOBSERVATIONAL

Enrollment

2,033

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

repaglinide

Repaglinide prescribed at the discretion of the investigator, according to local labelling, and evaluated at week 0, 8 and 16 of the study

Trial Locations (1)

100004

Beijing

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY